Get the Stockscreener App
2.70
1.82%
-0.05
Zentalis Pharmaceuticals Inc stock is traded at $2.70, with a volume of 1.07M.
It is down -1.82% in the last 24 hours and down -30.41% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$2.75
Open:
$2.75
24h Volume:
1.07M
Relative Volume:
0.87
Market Cap:
$255.61M
Revenue:
$26.87M
Net Income/Loss:
$-124.13M
P/E Ratio:
-1.5537
EPS:
-1.7378
Net Cash Flow:
$-125.60M
1W Performance:
-13.18%
1M Performance:
-30.41%
6M Performance:
+5.88%
1Y Performance:
+81.21%
1-Day Range:
$2.65
$2.77
1-Week Range:
$2.65
$3.15
52-Week Range:
$1.212
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.70 | 255.61M | 26.87M | -124.13M | -125.60M | -1.7378 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Resumed | Wells Fargo | Equal Weight |
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to S&P Global BMI Index - marketscreener.com
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis Pharmaceuticals stock gains after ovarian cancer trial update and insider buying - AD HOC NEWS
Zentalis Pharmaceuticals stock falls after public offering pricing and trades below recent highs - AD HOC NEWS
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales - Benzinga
William Blair Initiates Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating - Moomoo
ZNTL Initiates Coverage On by William Blair -- Rating Set to Out - GuruFocus
William Blair Initiates Zentalis Pharmaceuticals at Outperform - marketscreener.com
Zentalis at Morgan Stanley conference: azenosertib push gains shape By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Zentalis at Wells Fargo conference: azenosertib gains clearer path - Investing.com
Zentalis Pharmaceuticals stock gains as investor conferences highlight azenosertib program - ad-hoc-news.de
Zentalis to present at Wells Fargo, Morgan Stanley events | 2026-09-02 | Investing News - Stockhouse
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Four new hires get rights to buy 269,000 Zentalis shares - Stock Titan
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib (ZNTL) - Seeking Alpha
Zentalis (ZNTL) Earnings Snapshot: EPS Does Not Reach the Reported Estimate; After Earnings: Shares Move 3.19% HigherSaaS Earnings Trends - dars.gov.et
Zentalis (ZNTL) Q2 2026 Results: Reported EPS Misses Expectations in the Available Record; Share Move: The Stock Ends Down 1.70% in the Current UpdateReturn On Capital - vinanet.vn
Zentalis (ZNTL) Results Check: The EPS Result Is Below Expectation in the Available Record; Price Reaction: The Stock Records a 0.39% Decrease in the Available RecordEarnings Turnaround - vinanet.vn
Zentalis (ZNTL) Earnings Report: EPS Does Not Reach the Reported Estimate on the Day; Stock Move: The Share Price Adds 0.52% in the Latest ReadingFiscal Year Earnings - vinanet.vn
Zentalis Pharmaceuticals(ZNTL.US) 10% Shareholder Buys US$15.17 Million in Common Stock - Moomoo
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock - MarketBeat
Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock - Investing.com
Nearly one-fifth of Zentalis (NASDAQ: ZNTL) sits with one investor group - Stock Titan
Zentalis Pharma closes $92.6 million public offering - The Pharma Letter
Zentalis Pharmaceuticals closes $92.6 million stock offering By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals closes $92.6 million stock offering - Investing.com
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Zentalis Pharmaceuticals Announces Closing of Underwritten - GlobeNewswire
GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL - MarketBeat
Zentalis Pharmaceuticals Closes Offering of Common Shares - finance.yahoo.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering - lw.com
symbol__ Stock Quote Price and Forecast - CNN
Why is Zentalis Pharmaceuticals stock tumbling today? By Investing.com - Investing.com Canada
Why is Zentalis Pharmaceuticals stock tumbling today? - Investing.com
Zentalis Pharmaceuticals Shares Fall on Public Offering Pricing - Moomoo
Zentalis Pharmaceuticals (ZNTL) Prices $80.5M Public Offering to Fund Clinical Trials - GuruFocus
Zentalis Pharmaceuticals Prices $80.5 Million Offering to Fund Clinical Pipeline - marketscreener.com
Update: Zentalis Pharmaceuticals Shares Fall After Pricing $80.5 Million Offering to Fund Clinical Pipeline - finance.yahoo.com
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50 - Investing.com
Zentalis Pharmaceuticals Prices $80.5 Million Public Offering of Common Stock - Quiver Quantitative
Zentalis Sets $3.50 Share Price to Fund Clinical Trials - Stock Titan
Zentalis Pharmaceuticals Announces Pricing Of Underwritten Public Offering - TradingView
Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis - Stock Titan
Zentalis Pharmaceuticals announces public stock offering By Investing.com - Investing.com Australia
Zentalis Pharmaceuticals announces public stock offering - Investing.com
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering - TradingView
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zentalis Pharmaceuticals Inc Stock (ZNTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '26 |
Sale |
2.43 |
2,962 |
7,197 |
33,667 |
| Bruns Ingmar | Chief Medical Officer |
Feb 09 '26 |
Sale |
2.39 |
335 |
802 |
33,332 |
| Vultaggio Vincent | PAO and PFO |
Feb 06 '26 |
Sale |
2.43 |
29,951 |
72,772 |
156,779 |
| Vultaggio Vincent | PAO and PFO |
Feb 10 '26 |
Sale |
2.42 |
6,894 |
16,699 |
146,506 |
| Vultaggio Vincent | PAO and PFO |
Feb 09 '26 |
Sale |
2.39 |
3,379 |
8,086 |
153,400 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 06 '26 |
Sale |
2.43 |
7,866 |
19,112 |
80,022 |
| EASTLAND JULIA MARIE | CEO & President |
Feb 09 '26 |
Sale |
2.39 |
889 |
2,127 |
79,133 |
| Vultaggio Vincent | PAO and PFO |
Feb 02 '26 |
Sale |
2.55 |
2,540 |
6,477 |
187,286 |
| Vultaggio Vincent | PAO and PFO |
Feb 03 '26 |
Sale |
2.52 |
556 |
1,398 |
186,730 |
| WALTERS GROUP | 10% Owner |
Dec 31 '25 |
Buy |
1.20 |
6,459,973 |
7,751,968 |
13,509,973 |
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):